Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China
· Delayed Price · Currency is CNY 29.94
+1.97 (7.04%)
Apr 29, 2026, 3:00 PM CST
SHA:688319 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 22.26 | 20.76 | 17.56 | 26.58 | 107.96 | Upgrade
|
| Depreciation & Amortization | 37.72 | 32.47 | 30.81 | 25.3 | 23.04 | Upgrade
|
| Other Amortization | 5.34 | 3.53 | 3.15 | 3.43 | 1.64 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.01 | 0.03 | 0.15 | 0.15 | 0.01 | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.5 | -0.86 | -1.04 | -3.7 | -3.76 | Upgrade
|
| Provision & Write-off of Bad Debts | 13.21 | 10.19 | 1.72 | 12.18 | 9 | Upgrade
|
| Other Operating Activities | 28.04 | 6.67 | 5.66 | 9.13 | 0.12 | Upgrade
|
| Change in Accounts Receivable | -84.65 | -83.63 | 0.98 | -151.92 | -147.16 | Upgrade
|
| Change in Inventory | 9.71 | -13.57 | 1.68 | -7.96 | -27.28 | Upgrade
|
| Change in Accounts Payable | 75.13 | 19.06 | -12.3 | 64.46 | 81.2 | Upgrade
|
| Operating Cash Flow | 105.49 | -9.73 | 44 | -24.55 | 39.96 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | 89.49% | Upgrade
|
| Capital Expenditures | -98.81 | -207.32 | -169.88 | -200.69 | -69.71 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.03 | 0.03 | - | - | 0.01 | Upgrade
|
| Investment in Securities | -24.21 | -17.5 | 90 | 140 | -190 | Upgrade
|
| Other Investing Activities | 0.5 | 0.86 | 1.04 | 3.7 | 3.76 | Upgrade
|
| Investing Cash Flow | -122.49 | -223.93 | -78.84 | -56.99 | -255.94 | Upgrade
|
| Long-Term Debt Issued | 176.1 | 206.82 | 208.25 | 129.99 | 35 | Upgrade
|
| Total Debt Issued | 176.1 | 206.82 | 208.25 | 129.99 | 35 | Upgrade
|
| Long-Term Debt Repaid | -119.65 | -78.85 | -100.06 | -40 | -27.34 | Upgrade
|
| Total Debt Repaid | -119.65 | -78.85 | -100.06 | -40 | -27.34 | Upgrade
|
| Net Debt Issued (Repaid) | 56.45 | 127.97 | 108.19 | 89.99 | 7.66 | Upgrade
|
| Issuance of Common Stock | - | - | 10.38 | 17.65 | 371.81 | Upgrade
|
| Repurchase of Common Stock | -2.38 | -2.39 | - | - | - | Upgrade
|
| Common Dividends Paid | -14.72 | -29.68 | -5.99 | -4.25 | -1.03 | Upgrade
|
| Other Financing Activities | -14.95 | - | 16.68 | - | -9.64 | Upgrade
|
| Financing Cash Flow | 24.4 | 95.91 | 129.27 | 103.38 | 368.79 | Upgrade
|
| Net Cash Flow | 7.4 | -137.76 | 94.42 | 21.84 | 152.82 | Upgrade
|
| Free Cash Flow | 6.68 | -217.05 | -125.88 | -225.24 | -29.75 | Upgrade
|
| Free Cash Flow Margin | 0.95% | -36.86% | -25.37% | -41.14% | -6.11% | Upgrade
|
| Free Cash Flow Per Share | 0.02 | -0.54 | -0.31 | -0.56 | -0.08 | Upgrade
|
| Cash Income Tax Paid | 52.14 | 25.59 | 34.19 | 35 | 16.56 | Upgrade
|
| Levered Free Cash Flow | 13.44 | -200.57 | -140.57 | -198.44 | -67.11 | Upgrade
|
| Unlevered Free Cash Flow | 22.81 | -191.53 | -136.09 | -195.27 | -66.34 | Upgrade
|
| Change in Working Capital | -0.57 | -82.52 | -14 | -97.61 | -98.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.